loading...| Preferred Name | Oxaliplatin | |
| Synonyms |
|
|
| Definitions |
An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04) |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C1181 |
|
| Accepted_Therapeutic_Use_For |
Metastatic colorectal cancer; ovarian cancer |
|
| ALT_DEFINITION |
A drug used with other drugs to treat colorectal cancer that is advanced or has come back. It is also being studied in the treatment of other types of cancer. Eloxatin attaches to DNA in cells and may kill cancer cells. It is a type of platinum compound. |
|
| CAS_Registry |
61825-94-3 |
|
| CHEBI_ID |
CHEBI:31941 |
|
| Chemical_Formula |
C8H14N2O4Pt |
|
| code |
C1181 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04) |
|
| Display_Name |
Oxaliplatin |
|
| FDA_UNII_Code |
04ZR38536J |
|
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Oxaliplatin |
|
| Legacy Concept Name |
Oxaliplatin |
|
| Maps_To |
Oxaliplatin |
|
| NCI_Drug_Dictionary_ID |
42374 |
|
| NSC Number |
266046 |
|
| PDQ_Closed_Trial_Search_ID |
42374 |
|
| PDQ_Open_Trial_Search_ID |
42374 |
|
| Preferred_Name |
Oxaliplatin |
|
| prefixIRI |
NCIT:C1181 |
|
| prefLabel |
Oxaliplatin |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0069717 |
|
| subClassOf |